- Home
- UMAC vs TVRD Comparison
UMAC vs TVRD Comparison
Compare UMAC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- TVRD
- Stock Information
- Founded
- UMAC 2019
- TVRD 2017
- Country
- UMAC United States
- TVRD United States
- Employees
- UMAC N/A
- TVRD N/A
- Industry
- UMAC
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- UMAC
- TVRD Health Care
- Exchange
- UMAC Nasdaq
- TVRD Nasdaq
- Market Cap
- UMAC 267.7M
- TVRD 246.5M
- IPO Year
- UMAC 2024
- TVRD N/A
- Fundamental
- Price
- UMAC $9.18
- TVRD $4.13
- Analyst Decision
- UMAC Strong Buy
- TVRD Buy
- Analyst Count
- UMAC 3
- TVRD 7
- Target Price
- UMAC $19.33
- TVRD $51.67
- AVG Volume (30 Days)
- UMAC 4.6M
- TVRD 242.3K
- Earning Date
- UMAC 11-06-2025
- TVRD 11-13-2025
- Dividend Yield
- UMAC N/A
- TVRD N/A
- EPS Growth
- UMAC N/A
- TVRD N/A
- EPS
- UMAC N/A
- TVRD N/A
- Revenue
- UMAC $8,304,873.00
- TVRD N/A
- Revenue This Year
- UMAC $55.07
- TVRD N/A
- Revenue Next Year
- UMAC $146.69
- TVRD N/A
- P/E Ratio
- UMAC N/A
- TVRD N/A
- Revenue Growth
- UMAC 133.20
- TVRD N/A
- 52 Week Low
- UMAC $2.55
- TVRD $3.85
- 52 Week High
- UMAC $23.62
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- UMAC 36.65
- TVRD 21.32
- Support Level
- UMAC $9.43
- TVRD $3.87
- Resistance Level
- UMAC $11.39
- TVRD $4.45
- Average True Range (ATR)
- UMAC 1.13
- TVRD 0.31
- MACD
- UMAC -0.42
- TVRD 1.01
- Stochastic Oscillator
- UMAC 11.45
- TVRD 25.22
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.